Glint Pharmaceuticals

Glint Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on transforming ocular drug delivery through its proprietary drug-eluting contact lens platform. The company's core technology, licensed from the University of Florida, utilizes a Vitamin E nano barrier system integrated into standard silicone hydrogel contact lenses to enable the sustained and controlled release of medications over several days. This approach aims to overcome the limitations of traditional eye drops, such as poor patient compliance and rapid drug washout, by providing a more convenient and effective treatment method. Glint's lead candidate, ACL5, is a moxifloxacin-eluting lens currently in Phase 1/2 clinical trials for the treatment of corneal infections and abrasions. Additionally, the company is advancing programs for glaucoma, dry eye, and ocular inflammation, leveraging its platform's ability to deliver both single and combination drug therapies.